Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group. Kubackova K, et al. Among authors: bortlicek z. Target Oncol. 2015 Dec;10(4):557-63. doi: 10.1007/s11523-015-0366-9. Target Oncol. 2015. PMID: 25903462
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group. Buchler T, et al. Among authors: bortlicek z. Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30. Eur Urol. 2016. PMID: 26746623
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.
Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, Zemanova M, Fiala O, Kubackova K, Dusek L, Hornova J, Buchler T; Czech Renal Cell Cancer Cooperative Group. Poprach A, et al. Among authors: bortlicek z. Drugs Aging. 2016 Sep;33(9):655-63. doi: 10.1007/s40266-016-0390-1. Drugs Aging. 2016. PMID: 27541802
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Buchler T, Poprach A, Bortlicek Z, Lakomy R, Chloupková R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Hornova J, Fiala O, Kopecky J, Finek J, Dusek L, Melichar B; Czech Metastatic Renal Cancer Cooperative Group. Buchler T, et al. Among authors: bortlicek z. Clin Genitourin Cancer. 2017 Dec;15(6):e1047-e1053. doi: 10.1016/j.clgc.2017.06.006. Epub 2017 Jun 29. Clin Genitourin Cancer. 2017. PMID: 28720439
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T. Lakomy R, et al. Among authors: bortlicek z. BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5. BMC Cancer. 2017. PMID: 29268716 Free PMC article.
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group. Poprach A, et al. Among authors: bortlicek z. Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8. Urol Oncol. 2014. PMID: 24321257
76 results